In the BioHarmony Drug Report Database

"Preview" Icon

Icatibant

Firazyr (icatibant) is a protein pharmaceutical. Icatibant was first approved as Firazyr on 2008-07-11. It is used to treat hereditary angioedemas in the USA. It has been approved in Europe to treat hereditary angioedemas. The pharmaceutical is active against B2 bradykinin receptor. In addition, it is known to target B1 bradykinin receptor.

 

Trade Name

 

Firazyr
 

Common Name

 

icatibant
 

ChEMBL ID

 

CHEMBL2028850
 

Indication

 

hereditary angioedemas
 

Drug Class

 

Antiasthmatics (bradykinin antagonists)

Image (chem structure or protein)

Icatibant structure rendering